Abdominal Aortic Aneurysm Drug Market
Abdominal Aortic Aneurysm Drug Market Size, Share & Trends Analysis Report, By Drug Class (?-blockers, Angiotensin-Converting Enzyme Inhibitor (ACE inhibitors), Angiotensin-Receptor Blocker (ARB), Doxycycline, and Others), By Application (Hospital, Clinic, and Others), Forecast Period, (2026-2035)
Industry Overview
Abdominal aortic aneurysm (AAA) drug market was valued at $2,569.2 million in 2025 and is projected to reach $5,267.6 million by 2035, growing at a CAGR of 7.5% during the forecast period (2026-2035). The abdominal aortic aneurysm drug market is expanding as a result of increasing clinical adoption of pharmacological therapies to manage aneurysm progression and associated cardiovascular risks. Rising prevalence of hypertension and vascular disorders has led to a higher demand for targeted drug interventions, including ?-blockers, ACE inhibitors, and ARBs. Improved diagnostic capabilities and earlier detection of aneurysms are enabling the timely initiation of therapy, supporting consistent market growth. Healthcare providers are increasingly incorporating guideline-driven drug regimens to reduce the need for surgical intervention. Additionally, enhanced access to treatment in both developed and emerging regions is facilitating broader patient coverage.
Market Dynamics
Increasing Adoption of Pharmacological Management over Surgical Interventions
The AAA drug market is witnessing a growing preference for pharmacological management, particularly in patients with small or moderate aneurysms who are not immediate candidates for surgery. Drugs such as ?-blockers, ACE inhibitors, and ARBs are increasingly prescribed to slow aneurysm progression and manage blood pressure. This trend is supported by clinical evidence demonstrating efficacy in reducing rupture risk and improving patient outcomes. Healthcare providers are integrating these medications into routine care protocols, complementing diagnostic monitoring practices. The approach reduces surgical dependency, lowers healthcare costs, and improves patient quality of life. Consequently, pharmacological management is becoming a central driver of market growth.
Expansion of Market Access in Emerging Regions
Pharmaceutical companies are increasingly targeting emerging markets in Asia-Pacific, Latin America, and the Middle East to expand AAA drug availability. Improved healthcare infrastructure, rising awareness of cardiovascular conditions, and increasing prevalence of hypertension and vascular disorders are driving demand. Regulatory approvals and localized distribution networks are facilitating broader adoption in hospitals and clinics. Additionally, educational initiatives for healthcare professionals are encouraging guideline-based therapy, further supporting uptake. As a result, emerging markets are contributing to accelerated revenue growth and regional diversification of the global AAA drug market.
Market Segmentation
- Based on the drug class, the market is segmented into ?-blockers, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin-receptor blockers (ARBS), doxycycline, and others.
- Based on the application, the market is segmented into hospital, clinic, and others.
?-blockers Segment to Lead the Market with the Largest Share
The global abdominal aortic aneurysm drug market is expanding owing to the widespread use of ?-blockers in clinical management. These agents are effective in controlling blood pressure and reducing stress on the aortic wall, helping to slow aneurysm progression. Their well-established efficacy and safety profile make them a preferred first-line therapy among clinicians. Increasing awareness of pharmacological options for aneurysm management has further boosted their adoption. The consistent prescription of ?-blockers in hospitals and outpatient settings contributes significantly to market revenue. Consequently, ?-blockers remain a key driver of sustained growth in the AAA drug segment.
Hospital: A Key Segment in Market Growth
Hospitals continue to play a central role in the expansion of the abdominal aortic aneurysm drug market. They serve as the primary point of diagnosis and treatment for patients with aneurysms, ensuring early initiation of pharmacological therapy. Advanced healthcare infrastructure and specialized vascular units enable hospitals to manage complex cases effectively. Increased hospital-based prescriptions and adherence to treatment protocols are boosting overall drug consumption. Hospitals also facilitate access to combination therapy regimens and monitor patient outcomes closely.
Regional Outlook
The global abdominal aortic aneurysm drug market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Growing adoption of Targeted Pharmacological Therapies in Europe
The European abdominal aortic aneurysm drug market is witnessing steady growth driven by the adoption of targeted pharmacological therapies across hospitals and clinics. Increasing awareness of aneurysm risks and early detection programs are expanding the patient base for drug treatment. Regulatory support and reimbursement frameworks facilitate wider access to ?-blockers, ACE inhibitors, and related medications. Clinical guidelines promoting evidence-based management encourage physicians to integrate pharmacological interventions into standard care. Additionally, collaborations between pharmaceutical companies and healthcare providers enhance distribution and therapy availability. Collectively, these factors support continued revenue growth for AAA drugs across Europe.
North America Region Dominates the Market with Major Share
The North American abdominal aortic aneurysm drug market is expanding owing to the region’s advanced healthcare infrastructure and high prevalence of cardiovascular conditions. Early diagnosis of aneurysms through imaging and regular health screenings supports the timely initiation of drug therapy. Strong insurance coverage and reimbursement policies enhance patient access to essential medications. Physicians increasingly follow guideline-based treatment protocols, ensuring consistent adoption of ?-blockers, ACE inhibitors, and ARBs. Pharmaceutical companies are also strengthening distribution networks to meet growing demand. As a result, North America maintains a leading position in the global AAA drug market.
Market Players Outlook
The major companies operating in the global abdominal aortic aneurysm drug market include AstraZeneca plc, Johnson & Johnson, Novartis AG, Pfizer Inc., and Sanofi S.A., among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In January 2026, A Leicestershire farmer is the first person in the UK to join a revolutionary trial, led by the University of Leicester, to test whether the type 2 diabetes drug metformin can treat deadly abdominal aortic aneurysms (AAA). The largest drug trial for AAA ever, a collaboration between researchers in the UK, Australia, and New Zealand, will investigate whether the cheap and common drug can slow or prevent the growth of the aneurysms in the body’s largest artery while they are still small and at low risk of rupturing.
- In October 2025, Medtronic plc, a company in healthcare technology, announced it received US Food and Drug Administration (FDA) labeling approval1 for the Medtronic Endurant stent graft system, by adding ruptured abdominal aortic aneurysm (rAAA) clinical evidence and removing the rAAA treatment warning. This FDA labeling approval makes Medtronic the first and only company to remove the rAAA warning from its stent graft system Instructions for Use (IFU), aligning innovation with real-world practices and training to empower physicians to act confidently in emergency cases.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global abdominal aortic aneurysm drug market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Abdominal Aortic Aneurysm Drug Market Sales Analysis – Drug Class | Application ($ Million)
- Abdominal Aortic Aneurysm Drug Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Abdominal Aortic Aneurysm Drug Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Abdominal Aortic Aneurysm Drug Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Abdominal Aortic Aneurysm Drug Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Abdominal Aortic Aneurysm Drug Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Abdominal Aortic Aneurysm Drug Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Abdominal Aortic Aneurysm Drug Market Revenue and Share by Manufacturers
- Abdominal Aortic Aneurysm Drug Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- AstraZeneca plc
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Johnson & Johnson
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Novartis AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Sanofi S.A.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- AstraZeneca plc
- Key Company Analysis
- Global Abdominal Aortic Aneurysm Drug Market Sales Analysis by Drug Class ($ Million)
- ?-blockers
- Angiotensin-Converting Enzyme Inhibitor (ACE inhibitors)
- Angiotensin-Receptor Blocker (ARB)
- Doxycycline
- Others
- Global Abdominal Aortic Aneurysm Drug Market Sales Analysis by Application ($ Million)
- Hospital
- Clinic
- Others
- Regional Analysis
- North American Abdominal Aortic Aneurysm Drug Market Sales Analysis – Drug Class | Application | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Abdominal Aortic Aneurysm Drug Market Sales Analysis – Drug Class | Application | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Abdominal Aortic Aneurysm Drug Market Sales Analysis – Drug Class | Application | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Abdominal Aortic Aneurysm Drug Market Sales Analysis – Drug Class | Application | Country ($ Million)
- Macroeconomic Factors for Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- AbbVie Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Amgen Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Astellas Pharma Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bayer AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bristol?Myers Squibb Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cardinal Health, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cook Medical LLC
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Endologix LLC
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GlaxoSmithKline plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Johnson & Johnson
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co., Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takeda Pharmaceutical Co. Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Terumo Corp.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Teva Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- L. Gore & Associates, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AbbVie Inc.
1. Global Abdominal Aortic Aneurysm Drug Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
2. Global Abdominal Aortic Aneurysm ß-blockers Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Abdominal Aortic Aneurysm Angiotensin-Converting Enzyme Inhibitor (ACE inhibitors) Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Abdominal Aortic Aneurysm Angiotensin-Receptor Blocker (ARB) Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Abdominal Aortic Aneurysm Doxycycline Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Other Abdominal Aortic Aneurysm Drug Class Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Abdominal Aortic Aneurysm Drug Market Research and Analysis by Application, 2025–2035 ($ Million)
8. Global Abdominal Aortic Aneurysm Drug For Hospital Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Abdominal Aortic Aneurysm Drug For Clinic Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Abdominal Aortic Aneurysm Drug For Other Application Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Abdominal Aortic Aneurysm Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
12. North American Abdominal Aortic Aneurysm Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
13. North American Abdominal Aortic Aneurysm Drug Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
14. North American Abdominal Aortic Aneurysm Drug Market Research and Analysis by Application, 2025–2035 ($ Million)
15. European Abdominal Aortic Aneurysm Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
16. European Abdominal Aortic Aneurysm Drug Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
17. European Abdominal Aortic Aneurysm Drug Market Research and Analysis by Application, 2025–2035 ($ Million)
18. Asia-Pacific Abdominal Aortic Aneurysm Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
19. Asia-Pacific Abdominal Aortic Aneurysm Drug Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
20. Asia-Pacific Abdominal Aortic Aneurysm Drug Market Research and Analysis by Application, 2025–2035 ($ Million)
21. Rest of the World Abdominal Aortic Aneurysm Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
22. Rest of the World Abdominal Aortic Aneurysm Drug Market Research and Analysis by Drug Class, 2025–2035 ($ Million)
23. Rest of the World Abdominal Aortic Aneurysm Drug Market Research and Analysis by Application, 2025–2035 ($ Million)
1. Global Abdominal Aortic Aneurysm Drug Market Share by Drug Class, 2025 Vs 2035 (%)
2. Global Abdominal Aortic Aneurysm ß-blockers Drug Market Share by Region, 2025 Vs 2035 (%)
3. Global Abdominal Aortic Aneurysm Angiotensin-Converting Enzyme Inhibitor (ACE inhibitors) Drug Market Share by Region, 2025 Vs 2035 (%)
4. Global Abdominal Aortic Aneurysm Angiotensin-Receptor Blocker (ARB) Drug Market Share by Region, 2025 Vs 2035 (%)
5. Global Abdominal Aortic Aneurysm Doxycycline Drug Market Share by Region, 2025 Vs 2035 (%)
6. Global Other Abdominal Aortic Aneurysm Drug Class Market Share by Region, 2025 Vs 2035 (%)
7. Global Abdominal Aortic Aneurysm Drug Market Share by Application, 2025 Vs 2035 (%)
8. Global Abdominal Aortic Aneurysm Drug For Hospital Market Share by Region, 2025 Vs 2035 (%)
9. Global Abdominal Aortic Aneurysm Drug For Clinics Market Share by Region, 2025 Vs 2035 (%)
10. Global Abdominal Aortic Aneurysm Drug For Other Application Market Share by Region, 2025 Vs 2035 (%)
11. Global Abdominal Aortic Aneurysm Drug Market Research and Analysis by Region, 2025–2035 ($ Million)
12. US Abdominal Aortic Aneurysm Drug Market Size, 2025–2035 ($ Million)
13. Canada Abdominal Aortic Aneurysm Drug Market Size, 2025–2035 ($ Million)
14. UK Abdominal Aortic Aneurysm Drug Market Size, 2025–2035 ($ Million)
15. France Abdominal Aortic Aneurysm Drug Market Size, 2025–2035 ($ Million)
16. Germany Abdominal Aortic Aneurysm Drug Market Size, 2025–2035 ($ Million)
17. Italy Abdominal Aortic Aneurysm Drug Market Size, 2025–2035 ($ Million)
18. Spain Abdominal Aortic Aneurysm Drug Market Size, 2025–2035 ($ Million)
19. Russia Abdominal Aortic Aneurysm Drug Market Size, 2025–2035 ($ Million)
20. Rest of Europe Abdominal Aortic Aneurysm Drug Market Size, 2025–2035 ($ Million)
21. India Abdominal Aortic Aneurysm Drug Market Size, 2025–2035 ($ Million)
22. China Abdominal Aortic Aneurysm Drug Market Size, 2025–2035 ($ Million)
23. Japan Abdominal Aortic Aneurysm Drug Market Size, 2025–2035 ($ Million)
24. South Korea Abdominal Aortic Aneurysm Drug Market Size, 2025–2035 ($ Million)
25. Australia and New Zealand Abdominal Aortic Aneurysm Drug Market Size, 2025–2035 ($ Million)
26. ASEAN Economies Abdominal Aortic Aneurysm Drug Market Size, 2025–2035 ($ Million)
27. Rest of Asia-Pacific Abdominal Aortic Aneurysm Drug Market Size, 2025–2035 ($ Million)
28. Latin America Abdominal Aortic Aneurysm Drug Market Size, 2025–2035 ($ Million)
29. Middle East and Africa Abdominal Aortic Aneurysm Drug Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the Abdominal Aortic Aneurysm Drug Market in 2025 is estimated to be around $2,569.2 million.
North America holds the largest share in the Abdominal Aortic Aneurysm Drug Market.
Leading players in the Abdominal Aortic Aneurysm Drug Market include AstraZeneca plc, Johnson & Johnson, Novartis AG, Pfizer Inc., and Sanofi S.A., among others.
The Abdominal Aortic Aneurysm Drug Market is expected to grow at a CAGR of 7.5% from 2026 to 2035.
The Abdominal Aortic Aneurysm Drug Market growth is driven by rising prevalence of cardiovascular disorders and increasing demand for pharmacological therapies to manage aneurysm progression and complications.
